Medicare Program: Medicare Drug Price Negotiation Program and Medicare Prescription Drug Benefit Program

The Plasma Protein Therapeutics Association (PPTA) supports CMS's proposal to distinguish between products where a plasma-derived protein is the active pharmaceutical ingredient and those where it serves only as an adjuvant or excipient. They argue that this distinction aligns with statutory intent and FDA regulations, ensuring that only genuine plasma-derived therapies are excluded from the Medicare Drug Price Negotiation Program.

The commenter, writing as a patient, supports the Medicare Drug Price Negotiation Program but emphasizes that CMS must balance lower costs with ensuring medication availability, supply-chain transparency, and patient safety. They urge the agency to consider factors like shortages and treatment delays when evaluating the effects of negotiated prices.